{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:04:53Z","timestamp":1790949893433,"version":"4.1.0"},"reference-count":66,"publisher":"Keio Journal of Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Keio J. Med.","Keio j. med"],"published-print":{"date-parts":[[2025]]},"DOI":"10.2302\/kjm.2023-0011-ir","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T22:12:55Z","timestamp":1690927975000},"page":"42-51","source":"Crossref","is-referenced-by-count":9,"title":["Tuberous Sclerosis Complex"],"prefix":"10.2302","volume":"74","author":[{"given":"Mari","family":"Wataya-Kaneda","sequence":"first","affiliation":[{"name":"Department of Neurocutaneous Medicine, Division of Health Sciences,              Graduate School of Medicine, Osaka University, Osaka, Japan"},{"name":"Department of Dermatology, Graduate School of Medicine, Osaka University,              Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1082","reference":[{"key":"1","unstructured":"1. Rayer PF: Traite Theorique et Pratique des Maladies          de la Peau, 2nd edn. JB Bailiere, Bon, 1835."},{"key":"2","unstructured":"2. von Recklinghausen F: Ein Herz von einen          Neugeborene welches mehrere thels nach aussen, theils nach den Hohlein prominirende          Tumoren(myomata) trug. Monatschr Gebrutsheklkd 1862; 20: 1\u20132."},{"key":"3","unstructured":"3. Bourneville DM: Sclerose tubereuse des          circonvultions cerebrales:idotie et epilepsie hemiplegique. Arch Neurol 1880; 1:          81\u201391."},{"key":"4","unstructured":"4. Bourneville DM, Brissaud E: Encephalite ou          sclerose tubereuse des circonvultions cwrebrales. Arch Neurol 1881; 1:          390\u2013410."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Vogt, Priv.-Doz. Dr H: Zur Pathologie und          pathologischen Anatomie der verschiedenen Idiotieformen. pp. 106\u2013117. Eur Neurol 1908; 24:          106\u2013117. https:\/\/doi.org\/10.1159\/000211721","DOI":"10.1159\/000211721"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gunther M, Penrose LS: The genetics of epiloia. J          Genet 1935; 31: 413\u2013430. https:\/\/doi.org\/10.1007\/BF02982409","DOI":"10.1007\/BF02982409"},{"key":"7","unstructured":"7. Lagos JC, Gomez MR: Tuberous sclerosis:          reappraisal of a clinical entity. Mayo Clin Proc 1967; 42: 26\u201349.          PMID:5297238"},{"key":"8","unstructured":"8. Gomez MR: Criteria for Diagnosis in Tuberous          Sclerosis, 2nd edn. New York, Raven Press, 1988."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Slegtenhorst M, Hoogt R, Hermans C, Nellist M,          Janssen B, Verhoef S, Lindhout D, Ouweland A, Halley D, Young J, Burley M, Jeremiah S,          Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP,          Jones AC, Tachataki M, Ravine D, Sampson JR, Reeve MP, Richardson P, Wilmer F, Munro C,          Hawkins TL, Sepp T, Ali JB, Ward S, Green AJ, Yates JR, Kwiatkowska J, Henske EP, Short          MP, Haines JH, Jozwiak S, Kwiatkowski DJ: Identification of the tuberous sclerosis gene          TSC1 on chromosome 9q34. Science 1997; 277: 805\u2013808. PMID:9242607          https:\/\/doi.org\/10.1126\/science.277.5327.805","DOI":"10.1126\/science.277.5327.805"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. The European Chromosome 16 Tuberous Sclerosis          Consortium: Identification and characterization of the tuberous sclerosis gene on          chromosome 16. Cell 1993; 75: 1305\u20131315.          https:\/\/doi.org\/10.1016\/0092-8674(93)90618-Z","DOI":"10.1016\/0092-8674(93)90618-Z"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Roach ES, Gomez MR, Northrup H: Tuberous          sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child          Neurol 1998; 13: 624\u2013628. PMID:9881533          https:\/\/doi.org\/10.1177\/088307389801301206","DOI":"10.1177\/088307389801301206"},{"key":"12","unstructured":"12. Wataya-Kaneda M, Yoshida Y, Kubota Y, Tsuchida T,          Matsunaga K, Nakagawa H, Niimura M, Otsuka H, Nakayama K: Tuberous sclerosis complex          diagnostic criteria and treatment guidelines [in Japanese]. Nippon Hifuka Gakkai Zasshi          2008; 118: 1667\u20131676."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Potter CJ, Huang H, Xu T: Drosophila Tsc1          functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell          proliferation, and organ size. Cell 2001; 105: 357\u2013368. PMID:11348592          https:\/\/doi.org\/10.1016\/S0092-8674(01)00333-6","DOI":"10.1016\/S0092-8674(01)00333-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Inoki K, Li Y, Zhu T, Wu J, Guan KL: TSC2 is          phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4:          648\u2013657. PMID:12172553 https:\/\/doi.org\/10.1038\/ncb839","DOI":"10.1038\/ncb839"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis          J: Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling          by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003; 13:          1259\u20131268. PMID:12906785 https:\/\/doi.org\/10.1016\/S0960-9822(03)00506-2","DOI":"10.1016\/S0960-9822(03)00506-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Inoki K, Li Y, Xu T, Guan KL: Rheb GTPase is a          direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003; 17:          1829\u20131834. PMID:12869586 https:\/\/doi.org\/10.1101\/gad.1110003","DOI":"10.1101\/gad.1110003"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tee AR, Anjum R, Blenis J: Inactivation of the          tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide          3-kinase\/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem 2003; 278:          37288\u201337296. PMID:12867426 https:\/\/doi.org\/10.1074\/jbc.M303257200","DOI":"10.1074\/jbc.M303257200"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Franz DN, Leonard J, Tudor C, Chuck G, Care M,          Sethuraman G, Dinopoulos A, Thomas G, Crone KR: Rapamycin causes regression of          astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490\u2013498. PMID:16453317          https:\/\/doi.org\/10.1002\/ana.20784","DOI":"10.1002\/ana.20784"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Bissler JJ, McCormack FX, Young LR, Elwing JM,          Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN:          Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N          Engl J Med 2008; 358: 140\u2013151. PMID:18184959          https:\/\/doi.org\/10.1056\/NEJMoa063564","DOI":"10.1056\/NEJMoa063564"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Bissler JJ, Kingswood JC, Radzikowska E,          Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ,          Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K: Everolimus for          angiomyolipoma associated with tuberous sclerosis complex or sporadic          lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind,          placebo-controlled trial. Lancet 2013; 381: 817\u2013824. PMID:23312829          https:\/\/doi.org\/10.1016\/S0140-6736(12)61767-X","DOI":"10.1016\/S0140-6736(12)61767-X"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Franz DN, Belousova E, Sparagana S, Bebin EM,          Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ,          Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S:          Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with          tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled Phase          3 trial. Lancet 2013; 381: 125\u2013132. PMID:23158522          https:\/\/doi.org\/10.1016\/S0140-6736(12)61134-9","DOI":"10.1016\/S0140-6736(12)61134-9"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Franz DN, Belousova E, Sparagana S, Bebin EM,          Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ,          Berkowitz N, Anak O, Niolat J, Jozwiak S: Everolimus for subependymal giant cell          astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of          the randomised EXIST-1 study. Lancet Oncol 2014; 15: 1513\u20131520. PMID:25456370          https:\/\/doi.org\/10.1016\/S1470-2045(14)70489-9","DOI":"10.1016\/S1470-2045(14)70489-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Northrup H, Krueger DA, Northrup H, Krueger DA,          Roberds S, Smith K, Sampson J, Korf B, Kwiatkowski DJ, Mowat D, Nellist M, Northrup H,          Povey S, de Vries P, Byars A, Dunn D, Ess K, Hook D, Jansen A, King B, Sahin M, Whittemore          V, Thiele E, Bebin EM, Chugani HT, Crino P, Curatolo P, Holmes G, Nabbout R, O\u2019Callaghan          F, Wheless J, Wu J, Darling TN, Cowen EW, Gosnell E, Hebert A, Mlynarczyk G, Soltani K,          Teng J, Wataya-Kaneda M, Witman PM, Kingswood C, Bissler J, Budde K, Hulbert J,          Guay-Woodford L, Sampson J, Sauter M, Zonneberg B, J\u00f3\u017awiak S, Bartels U, Berhouma M, Franz          DN, Koenig MK, Krueger DA, Roach ES, Roth J, Wang H, Weiner H, McCormack FX, Almoosa K,          Brody A, Burger C, Cottin V, Finlay G, Glass J, Henske EP, Johnson S, Kotloff R, Lynch D,          Moss J, Smith K, Rhu J, Da Silva AT, Young LR, Knilans T, Hinton R, Prakash A, Romp R,          Singh AD, DebRoy A, Chen PL, Sparagana S, Frost MD, International Tuberous Sclerosis          Complex Consensus Group: Tuberous sclerosis complex diagnostic criteria update:          recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.          Pediatr Neurol 2013; 49: 243\u2013254. PMID:24053982          https:\/\/doi.org\/10.1016\/j.pediatrneurol.2013.08.001","DOI":"10.1016\/j.pediatrneurol.2013.08.001"},{"key":"24","unstructured":"24. Wataya-Kaneda M, Mizuguchi M, Hatano T, Seyama Y,          Hino O, Nishigori CH: Revised tuberous sclerosis complex diagnostic criteria and treatment          guidelines [in Japanese]. Nippon Hifuka Gakkai Zasshi 2018; 128: 1\u201316."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ishii R, Wataya-Kaneda M, Canuet L, Nonomura N,          Nakai Y, Takeda M. Everolimus improves behavioral deficits in a patient with autism          associated with tuberous sclerosis: a case report. Neuropsychiatr Electrophysiol 2015; 1:          6.","DOI":"10.1186\/s40810-015-0004-x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Curatolo P: Mechanistic target of rapamycin          (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol 2015; 52:          281\u2013289. PMID:25591831          https:\/\/doi.org\/10.1016\/j.pediatrneurol.2014.10.028","DOI":"10.1016\/j.pediatrneurol.2014.10.028"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Krueger DA, Wilfong AA, Holland-Bouley K,          Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN: Everolimus treatment          of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013; 74: 679\u2013687.          PMID:23798472 https:\/\/doi.org\/10.1002\/ana.23960","DOI":"10.1002\/ana.23960"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ehninger D, Silva AJ: Rapamycin for treating          tuberous sclerosis and autism spectrum disorders. Trends Mol Med 2011; 17: 78\u201387.          PMID:21115397 https:\/\/doi.org\/10.1016\/j.molmed.2010.10.002","DOI":"10.1016\/j.molmed.2010.10.002"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Canuet L, Ishii R, Iwase M, Kurimoto R, Ikezawa          K, Azechi M, Wataya-Kaneda M, Takeda M: Tuberous sclerosis: localizing the epileptogenic          tuber with synthetic aperture magnetometry with excess kurtosis analysis. J Clin Neurosci          2008; 15: 1296\u20131298. PMID:18778940          https:\/\/doi.org\/10.1016\/j.jocn.2007.03.030","DOI":"10.1016\/j.jocn.2007.03.030"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto          S, Katayama I: A topical combination of rapamycin and tacrolimus for the treatment of          angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese          patients with TSC of different disease severity. Br J Dermatol 2011; 165: 912\u2013916.          PMID:21692771 https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10471.x","DOI":"10.1111\/j.1365-2133.2011.10471.x"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto          S, Katayama I: A novel application of topical rapamycin formulation, an inhibitor of mTOR,          for patients with hypomelanotic macules in tuberous sclerosis complex. Arch Dermatol 2012;          148: 138\u2013139. PMID:22250258 https:\/\/doi.org\/10.1001\/archderm.148.1.138","DOI":"10.1001\/archderm.148.1.138"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Wataya-Kaneda M, Tanaka M, Yang L, Yang F,          Tsuruta D, Nakamura A, Matsumoto S, Hamasaki T, Tanemura A, Katayama I: Clinical and          histologic analysis of the efficacy of topical rapamycin therapy against hypomelanotic          macules in tuberous sclerosis complex. JAMA Dermatol 2015; 151: 722\u2013730. PMID:25692384          https:\/\/doi.org\/10.1001\/jamadermatol.2014.4298","DOI":"10.1001\/jamadermatol.2014.4298"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Wataya-Kaneda M, Nakamura A, Tanaka M, Hayashi M,          Matsumoto S, Yamamoto K, Katayama I: Efficacy and safety of topical sirolimus therapy for          facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial. JAMA          Dermatol 2017; 153: 39\u201348. PMID:27837201          https:\/\/doi.org\/10.1001\/jamadermatol.2016.3545","DOI":"10.1001\/jamadermatol.2016.3545"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Wataya-Kaneda M, Ohno Y, Fujita Y, Yokozeki H,          Niizeki H, Ogai M, Fukai K, Nagai H, Yoshida Y, Hamada I, Hio T, Shimizu K, Murota H:          Sirolimus gel treatment vs placebo for facial angiofibromas in patients with tuberous          sclerosis complex: a randomized clinical trial. JAMA Dermatol 2018; 154: 781\u2013788.          PMID:29800026 https:\/\/doi.org\/10.1001\/jamadermatol.2018.1408","DOI":"10.1001\/jamadermatol.2018.1408"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kingswood JC, Jozwiak S, Belousova ED, Frost MD,          Kuperman RA, Bebin EM, Korf BR, Flamini JR, Kohrman MH, Sparagana SP, Wu JY, Brechenmacher          T, Stein K, Berkowitz N, Bissler JJ, Franz DN: The effect of everolimus on renal          angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal          giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3          trial EXIST-1. Nephrol Dial Transplant 2014; 29: 1203\u20131210. PMID:24729041          https:\/\/doi.org\/10.1093\/ndt\/gfu013","DOI":"10.1093\/ndt\/gfu013"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Fisher OD, Stevenson AC: Frequency of epiloia in          Northern Ireland. Br J Prev Soc Med 1956; 10: 134\u2013135. PMID:13374272","DOI":"10.1136\/jech.10.3.134"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Nevin NC, Pearce WG: Diagnostic and genetical          aspects of tuberous sclerosis. J Med Genet 1968; 5: 273\u2013280. PMID:5713638          https:\/\/doi.org\/10.1136\/jmg.5.4.273","DOI":"10.1136\/jmg.5.4.273"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Sampson JR, Scahill SJ, Stephenson JB, Mann L,          Connor JM: Genetic aspects of tuberous sclerosis in the west of Scotland. J Med Genet          1989; 26: 28\u201331. PMID:2918523 https:\/\/doi.org\/10.1136\/jmg.26.1.28","DOI":"10.1136\/jmg.26.1.28"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Morrison PJ, Shepherd CH, Stewart FJ, Nevin NC:          Prevalence of tuberous sclerosis in UK. Lancet 1998; 352: 318\u2013319. PMID:9690431          https:\/\/doi.org\/10.1016\/S0140-6736(05)60291-7","DOI":"10.1016\/S0140-6736(05)60291-7"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Wataya-Kaneda M, Tanaka M, Hamasaki T, Katayama          I: Trends in the prevalence of tuberous sclerosis complex manifestations: an          epidemiological study of 166 Japanese patients. PLoS One 2013; 8: e63910. PMID:23691114          https:\/\/doi.org\/10.1371\/journal.pone.0063910","DOI":"10.1371\/journal.pone.0063910"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Wolfson RL, Chantranupong L, Saxton RA, Shen K,          Scaria SM, Cantor JR, Sabatini DM: Sestrin2 is a leucine sensor for the mTORC1 pathway.          Science 2016; 351: 43\u201348. PMID:26449471          https:\/\/doi.org\/10.1126\/science.aab2674","DOI":"10.1126\/science.aab2674"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Chantranupong L, Scaria SM, Saxton RA, Gygi MP,          Shen K, Wyant GA, Wang T, Harper JW, Gygi SP, Sabatini DM: The CASTOR proteins are          arginine sensors for the mTORC1 pathway. Cell 2016; 165: 153\u2013164. PMID:26972053          https:\/\/doi.org\/10.1016\/j.cell.2016.02.035","DOI":"10.1016\/j.cell.2016.02.035"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Niida Y, Stemmer-Rachamimov AO, Logrip M, Tapon          D, Perez R, Kwiatkowski DJ, Sims K, MacCollin M, Louis DN, Ramesh V: Survey of somatic          mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic          mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 2001; 69: 493\u2013503.          PMID:11468687 https:\/\/doi.org\/10.1086\/321972","DOI":"10.1086\/321972"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto          A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela          D, Kwiatkowski DJ: Mutational analysis in a cohort of 224 tuberous sclerosis patients          indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J          Hum Genet 2001; 68: 64\u201380. PMID:11112665 https:\/\/doi.org\/10.1086\/316951","DOI":"10.1086\/316951"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Au KS, Williams AT, Roach ES, Batchelor L,          Sparagana SP, Delgado MR, Wheless JW, Baumgartner JE, Roa BB, Wilson CM, Smith-Knuppel TK,          Cheung MY, Whittemore VH, King TM, Northrup H: Genotype\/phenotype correlation in 325          individuals referred for a diagnosis of tuberous sclerosis complex in the United States.          Genet Med 2007; 9: 88\u2013100. PMID:17304050          https:\/\/doi.org\/10.1097\/GIM.0b013e31803068c7","DOI":"10.1097\/GIM.0b013e31803068c7"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Sancak O, Nellist M, Goedbloed M, Elfferich P,          Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A:          Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype\u2013phenotype          correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex.          Eur J Hum Genet 2005; 13: 731\u2013741. PMID:15798777          https:\/\/doi.org\/10.1038\/sj.ejhg.5201402","DOI":"10.1038\/sj.ejhg.5201402"},{"key":"47","unstructured":"47. de Vries PJ, Belousova E, Benedik MP, Carter T,          Cottin V, Curatolo P, Dahlin M, D\u2019Amato L, Beaure d\u2019Aug\u00e8res G, Ferreira JC, Feucht M,          Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, Nabbout R,          O\u2019Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S,          Zonnenberg B, Kingswood JC, Jansen AC, TOSCA Investigators: Tuberous sclerosis          complex-associated neuropsychiatric disorders (TAND): new findings on age, sex, and          genotype in relation to intellectual phenotype. Front Neurol 2020; 11: 603.          PMID:32733359"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Carsillo T, Astrinidis A, Henske EP: Mutations in          the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary          lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000; 97: 6085\u20136090. PMID:10823953          https:\/\/doi.org\/10.1073\/pnas.97.11.6085","DOI":"10.1073\/pnas.97.11.6085"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Krueger DA, Northrup H, International Tuberous          Sclerosis Complex Consensus Group: Tuberous sclerosis complex surveillance and management:          recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.          Pediatr Neurol 2013; 49: 255\u2013265. PMID:24053983          https:\/\/doi.org\/10.1016\/j.pediatrneurol.2013.08.002","DOI":"10.1016\/j.pediatrneurol.2013.08.002"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Northrup H, Aronow ME, Bebin EM, Bissler J,          Darling TN, de Vries PJ, Frost MD, Fuchs Z, Gosnell ES, Gupta N, Jansen AC, J\u00f3\u017awiak S,          Kingswood JC, Knilans TK, McCormack FX, Pounders A, Roberds SL, Rodriguez-Buritica DF,          Roth J, Sampson JR, Sparagana S, Thiele EA, Weiner HL, Wheless JW, Towbin AJ, Krueger DA,          International Tuberous Sclerosis Complex Consensus Group: Updated international tuberous          sclerosis complex diagnostic criteria and surveillance and management recommendations.          Pediatr Neurol 2021; 123: 50\u201366. PMID:34399110          https:\/\/doi.org\/10.1016\/j.pediatrneurol.2021.07.011","DOI":"10.1016\/j.pediatrneurol.2021.07.011"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Cook JA, Oliver K, Mueller RF, Sampson J: A cross          sectional study of renal involvement in tuberous sclerosis. J Med Genet 1996; 33: 480\u2013484.          PMID:8782048 https:\/\/doi.org\/10.1136\/jmg.33.6.480","DOI":"10.1136\/jmg.33.6.480"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Rakowski SK, Winterkorn EB, Paul E, Steele DJ,          Halpern EF, Thiele EA: Renal manifestations of tuberous sclerosis complex: incidence,          prognosis, and predictive factors. Kidney Int 2006; 70: 1777\u20131782. PMID:17003820          https:\/\/doi.org\/10.1038\/sj.ki.5001853","DOI":"10.1038\/sj.ki.5001853"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Ewalt DH, Sheffield E, Sparagana SP, Delgado MR,          Roach S: Renal lesion growth in children with tuberous sclerosis complex. J Urol 1998;          160: 141\u2013145. PMID:9628635 https:\/\/doi.org\/10.1016\/S0022-5347(01)63072-6","DOI":"10.1016\/S0022-5347(01)63072-6"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Borkowska J, Schwartz RA, Kotulska K, Jozwiak S:          Tuberous sclerosis complex: tumors and tumorigenesis. Int J Dermatol 2011; 50: 13\u201320.          PMID:21182496 https:\/\/doi.org\/10.1111\/j.1365-4632.2010.04727.x","DOI":"10.1111\/j.1365-4632.2010.04727.x"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Crino PB, Nathanson KL, Henske EP: The tuberous          sclerosis complex. N Engl J Med 2006; 355: 1345\u20131356. PMID:17005952          https:\/\/doi.org\/10.1056\/NEJMra055323","DOI":"10.1056\/NEJMra055323"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Maruyama H, Ohbayashi C, Hino O, Tsutsumi M,          Konishi Y: Pathogenesis of multifocal micronodular pneumocyte hyperplasia and          lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis          genes TSC1 and TSC2. Pathol Int 2001; 51: 585\u2013594. PMID:11564212          https:\/\/doi.org\/10.1046\/j.1440-1827.2001.01242.x","DOI":"10.1046\/j.1440-1827.2001.01242.x"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Kobayashi T, Satoh K, Ohkawa M: Multifocal          micronodular pneumocyte hyperplasia associated with tuberous sclerosis. Acta Radiol 2005;          46: 37\u201340. PMID:15841738 https:\/\/doi.org\/10.1080\/02841850510020860","DOI":"10.1080\/02841850510020860"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Kobashi Y, Yoshida K, Miyashita N, Niki Y,          Matsushima T, Irei T: Multifocal micronodular pneumocyte hyperplasia in a man with          tuberous sclerosis. Intern Med 2005; 44: 462\u2013466. PMID:15942095          https:\/\/doi.org\/10.2169\/internalmedicine.44.462","DOI":"10.2169\/internalmedicine.44.462"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Teng JM, Cowen EW, Wataya-Kaneda M, Gosnell ES,          Witman PM, Hebert AA, Mlynarczyk G, Soltani K, Darling TN: Dermatologic and dental aspects          of the 2012 International Tuberous Sclerosis Complex Consensus Statements. JAMA Dermatol          2014; 150: 1095\u20131101.","DOI":"10.1001\/jamadermatol.2014.938"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Kwiatkowski JD, Whittemore HV, Thiele AE: Tuberous          sclerosis complex. Wiley-Blackwell Press; 2010.","DOI":"10.1002\/9783527630073"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Dabora SL, Franz DN, Ashwal S, Sagalowsky A,          DiMario FJ, Miles D, Cutler D, Krueger D, Uppot RN, Rabenou R, Camposano S, Paolini J,          Fennessy F, Lee N, Woodrum C, Manola J, Garber J, Thiele EA: Multicenter Phase 2 trial of          sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and          VEGF- D levels decrease. PLoS One 2011; 6: e23379. PMID:21915260          https:\/\/doi.org\/10.1371\/journal.pone.0023379","DOI":"10.1371\/journal.pone.0023379"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Pallet N, Legendre C: Adverse events associated          with mTOR inhibitors. Expert Opin Drug Saf 2013; 12: 177\u2013186. PMID:23252795          https:\/\/doi.org\/10.1517\/14740338.2013.752814","DOI":"10.1517\/14740338.2013.752814"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Haemel AK, O\u2019Brian AL, Teng JM: Topical          rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol          2010; 146: 715\u2013718. PMID:20644030          https:\/\/doi.org\/10.1001\/archdermatol.2010.125","DOI":"10.1001\/archdermatol.2010.125"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Koenig MK, Hebert AA, Roberson J, Samuels J,          Slopis J, Woerner A, Northrup H: Topical rapamycin therapy to alleviate the cutaneous          manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial          to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D 2012; 12:          121\u2013126. PMID:22934754 https:\/\/doi.org\/10.2165\/11634580-000000000-00000","DOI":"10.1007\/BF03262196"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Tu J, Foster RS, Bint LJ, Halbert AR: Topical          rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a          pilot study and promising future directions. Australas J Dermatol 2014; 55: 63\u201369.          PMID:24359523 https:\/\/doi.org\/10.1111\/ajd.12125","DOI":"10.1111\/ajd.12125"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Wataya-Kaneda M, Nagai H, Ohno Y, Yokozeki H,          Fujita Y, Niizeki H, Yoshida K, Ogai M, Yoshida Y, Asahina A, Fukai K, Tateishi C, Hamada          I, Takahata T, Shimizu K, Shimasaki S, Murota H: Safety and efficacy of the sirolimus gel          for TSC patients with facial skin lesions in a long-term, open-label, extension,          uncontrolled clinical trial. Dermatol Ther (Heidelb) 2020; 10: 635\u2013650. PMID:32385845          https:\/\/doi.org\/10.1007\/s13555-020-00387-7","DOI":"10.1007\/s13555-020-00387-7"}],"container-title":["The Keio Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kjm\/74\/1\/74_2023-0011-IR\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:04:29Z","timestamp":1743221069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kjm\/74\/1\/74_2023-0011-IR\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2302\/kjm.2023-0011-ir","relation":{},"ISSN":["0022-9717","1880-1293"],"issn-type":[{"value":"0022-9717","type":"print"},{"value":"1880-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"2023-0011-IR"}}